目的:探讨NF-КB,血管紧张素Ⅱ-1型受体(ATIR)在非酒精性脂肪肝病(NAFLD)发病中的作用及其机制。方法:采用改良高脂饮食建立大鼠NAFLD模型,随机分为正常组普通饲料喂养,模型组高脂饮食喂养,干预组高脂饮食饲养10周后吡咯烷二硫基甲酸酯(...目的:探讨NF-КB,血管紧张素Ⅱ-1型受体(ATIR)在非酒精性脂肪肝病(NAFLD)发病中的作用及其机制。方法:采用改良高脂饮食建立大鼠NAFLD模型,随机分为正常组普通饲料喂养,模型组高脂饮食喂养,干预组高脂饮食饲养10周后吡咯烷二硫基甲酸酯(PDTC)腹腔注射4周,分别于10、14周处死各组大鼠,观察肝组织病理学形态;测定血管紧张素浓度;检测NF-KB蛋白、肝脏AT1R在肝细胞中的表达情况。结果:肝组织病理结果提示正常组肝组织结构正常;模型组大鼠肝组织出现脂肪变性并随造模时间的延长而加重,10、14周大鼠肝脏可见气球样变及程度不等的肝细胞坏死和小叶内炎症、腺泡内散在点灶状坏死,部分可见点灶状坏死成片,门管区轻中度炎症。14周大鼠出现胶原纤维生成。免疫组化结果提示模型组大鼠肝细胞内可见NF-КB明显活化,而且随造模时间延长,其表达随之增多;干预组表达低于同期模型组,但高于正常组。放免法结果提示模型组、干预组血管紧张素浓度均高于正常组,且随着造模时间的延长,其浓度逐渐增多;干预组血管紧张素浓度低于同时期模型组但高于正常组。RT-PCR法显示:AT1Rm RNA表达量在模型组中随着造模时间的延长,表达量逐渐增加,且均明显高于同时间段正常组;干预组表达低于同时期模型组但高于正常组。结论:NAFLD肝组织随着疾病程度加重,NF-КB活性增强,抑制其活性可降低NAFLD大鼠肝组织AT1R m RNA表达。展开更多
Using the latest reported homologous Chemokine receptors （PDB ID： 3ODU, 3OE0 and 3OE6） as templates, twenty models of angiotensin II （Ang II） type 1 （AT1） receptor （known as p30556） were generated by multiple...Using the latest reported homologous Chemokine receptors （PDB ID： 3ODU, 3OE0 and 3OE6） as templates, twenty models of angiotensin II （Ang II） type 1 （AT1） receptor （known as p30556） were generated by multiple templates homology modeling. According to the results of the initial validation of these twenty models, the model 0020 was finally chosen as the best one for further studies. Then, a 2 ns molecular dynamic （MD） simulation for model 0020 was conducted in normal saline （0.9%, w/F） under periodical boundary conditions, which was followed by docking studies of model 0020 with several existing AT1 receptor blockers （ARBs）. The docking results reveal that model 0020 possesses good affinities with these docked ARBs which are in accordance with both the IC50 inhibitor values and their curative effects. The results also show more potent interactions between the model 0020 and its ARBs than those of ever reported results, such as hydrogen bonds, hydrophobic interactions, and especially cation-n interactions and π-π interactions which have never been reported before. This may reveal that the structure of the model 0020 is quite close to its real crystal structure and the model 0020 may have the potential to be used for structure based drug design：展开更多
文摘目的:探讨NF-КB,血管紧张素Ⅱ-1型受体(ATIR)在非酒精性脂肪肝病(NAFLD)发病中的作用及其机制。方法:采用改良高脂饮食建立大鼠NAFLD模型,随机分为正常组普通饲料喂养,模型组高脂饮食喂养,干预组高脂饮食饲养10周后吡咯烷二硫基甲酸酯(PDTC)腹腔注射4周,分别于10、14周处死各组大鼠,观察肝组织病理学形态;测定血管紧张素浓度;检测NF-KB蛋白、肝脏AT1R在肝细胞中的表达情况。结果:肝组织病理结果提示正常组肝组织结构正常;模型组大鼠肝组织出现脂肪变性并随造模时间的延长而加重,10、14周大鼠肝脏可见气球样变及程度不等的肝细胞坏死和小叶内炎症、腺泡内散在点灶状坏死,部分可见点灶状坏死成片,门管区轻中度炎症。14周大鼠出现胶原纤维生成。免疫组化结果提示模型组大鼠肝细胞内可见NF-КB明显活化,而且随造模时间延长,其表达随之增多;干预组表达低于同期模型组,但高于正常组。放免法结果提示模型组、干预组血管紧张素浓度均高于正常组,且随着造模时间的延长,其浓度逐渐增多;干预组血管紧张素浓度低于同时期模型组但高于正常组。RT-PCR法显示:AT1Rm RNA表达量在模型组中随着造模时间的延长,表达量逐渐增加,且均明显高于同时间段正常组;干预组表达低于同时期模型组但高于正常组。结论:NAFLD肝组织随着疾病程度加重,NF-КB活性增强,抑制其活性可降低NAFLD大鼠肝组织AT1R m RNA表达。
基金Project(20876180)supported by the National Natural Science Foundation of China
文摘Using the latest reported homologous Chemokine receptors （PDB ID： 3ODU, 3OE0 and 3OE6） as templates, twenty models of angiotensin II （Ang II） type 1 （AT1） receptor （known as p30556） were generated by multiple templates homology modeling. According to the results of the initial validation of these twenty models, the model 0020 was finally chosen as the best one for further studies. Then, a 2 ns molecular dynamic （MD） simulation for model 0020 was conducted in normal saline （0.9%, w/F） under periodical boundary conditions, which was followed by docking studies of model 0020 with several existing AT1 receptor blockers （ARBs）. The docking results reveal that model 0020 possesses good affinities with these docked ARBs which are in accordance with both the IC50 inhibitor values and their curative effects. The results also show more potent interactions between the model 0020 and its ARBs than those of ever reported results, such as hydrogen bonds, hydrophobic interactions, and especially cation-n interactions and π-π interactions which have never been reported before. This may reveal that the structure of the model 0020 is quite close to its real crystal structure and the model 0020 may have the potential to be used for structure based drug design：
